Next Article in Journal
Elevated Mutation Burdens in Canadian Oat and Wheat Cultivars Released over the Past Century
Next Article in Special Issue
9-cis-Retinoic Acid Improves Disease Modelling in iPSC-Derived Liver Organoids
Previous Article in Journal
Absence of Microglial Activation and Maintained Hippocampal Neurogenesis in a Transgenic Mouse Model of Crohn’s Disease
Previous Article in Special Issue
Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Brain Organoids and Assembloids—From Disease Modeling to Drug Discovery

by
Aderonke O. Ajongbolo
1,2 and
Sigrid A. Langhans
1,*
1
Division of Neurology, Nemours Children’s Health, Wilmington, DE 19803, USA
2
Biological Sciences Graduate Program, University of Delaware, Newark, DE 19716, USA
*
Author to whom correspondence should be addressed.
Cells 2025, 14(11), 842; https://doi.org/10.3390/cells14110842
Submission received: 4 May 2025 / Revised: 2 June 2025 / Accepted: 2 June 2025 / Published: 4 June 2025
(This article belongs to the Special Issue Organoids as an Experimental Tool)

Abstract

Brain organoids are self-organized, three-dimensional (3D) aggregates derived from human embryonic stem cells, induced pluripotent stem cells, or primary organs with cell types and cellular architectures resembling those of the developing human brain. Recent studies have shown the use of region-specific brain organoids for modeling various diseases ranging from neurodevelopmental and neurodegenerative diseases to different brain cancers, which have numerous applications in fundamental research and the development of new drugs, personalized treatment, and regenerative medicine. Consequently, the use of brain organoids in drug discovery is complex and challenging and still an emerging area in this field. This review article summarizes the primary stem cells used in brain organoid generation, region-specific brain organoids, and the functional assays used in their characterization. In addition, we discuss the use of brain organoids in modeling neurodevelopmental and neurodegenerative diseases and pediatric brain cancers, as well as the application of organoids, assembloids, and tumoroids in cancer neuroscience. We further explore the recent advances in using brain organoids in high-throughput screening to improve their use for drug discovery.
Keywords: brain; cerebellum; organoid; neurodevelopmental disease; neuropsychiatric disorder; neurodegeneration; substance abuse; brain cancer; high-throughput screening (HTS); drug discovery; cancer neuroscience brain; cerebellum; organoid; neurodevelopmental disease; neuropsychiatric disorder; neurodegeneration; substance abuse; brain cancer; high-throughput screening (HTS); drug discovery; cancer neuroscience
Graphical Abstract

Share and Cite

MDPI and ACS Style

Ajongbolo, A.O.; Langhans, S.A. Brain Organoids and Assembloids—From Disease Modeling to Drug Discovery. Cells 2025, 14, 842. https://doi.org/10.3390/cells14110842

AMA Style

Ajongbolo AO, Langhans SA. Brain Organoids and Assembloids—From Disease Modeling to Drug Discovery. Cells. 2025; 14(11):842. https://doi.org/10.3390/cells14110842

Chicago/Turabian Style

Ajongbolo, Aderonke O., and Sigrid A. Langhans. 2025. "Brain Organoids and Assembloids—From Disease Modeling to Drug Discovery" Cells 14, no. 11: 842. https://doi.org/10.3390/cells14110842

APA Style

Ajongbolo, A. O., & Langhans, S. A. (2025). Brain Organoids and Assembloids—From Disease Modeling to Drug Discovery. Cells, 14(11), 842. https://doi.org/10.3390/cells14110842

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop